View in EDS

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.

Saved in:
Bibliographic Details
Title: Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Authors: Silk JD; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com., Abbott RJM; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Adams KJ; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Bennett AD; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Brett S; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Cornforth TV; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Crossland KL; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Figueroa DJ; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Jing J; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., O'Connor C; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Pachnio A; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Patasic L; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Peredo CE; Cell and Gene Therapy Product Development and Supply, Analytical Development, GlaxoSmithKline, Collegeville, PA., Quattrini A; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Quinn LL; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Rust AG; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Saini M; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Sanderson JP; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Steiner D; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Tavano B; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Viswanathan P; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Wiedermann GE; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Wong R; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Jakobsen BK; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Britten CM; Oncology Research and Development, GlaxoSmithKline, Stevenage Herts, United Kingdom; and., Gerry AB; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom., Brewer JE; Adaptimmune Ltd., Milton Park, Abingdon, United Kingdom; jonathan.silk@enarabio.com joanna.brewer@adaptimmune.com.
Source: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2022 Jan 01; Vol. 208 (1), pp. 169-180. Date of Electronic Publication: 2021 Dec 01.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 2985117R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1550-6606
DOI:10.4049/jimmunol.2001357